What You Should Know About PTEN Pathogenic/Likely Pathogenic Variants
Individuals with a pathogenic/likely pathogenic (P/LP) variant in the PTEN gene have PTEN hamartoma tumor syndrome (PHTS), which is a spectrum of several conditions that have overlapping features. This spectrum includes Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and PTEN-related autism spectrum. PHTS can cause noncancerous, tumor-like growths called hamartomas throughout the body. There is also an increased risk for several types of cancer, including breast, thyroid, kidney, uterine, colon, and skin cancers.
UT Southwestern Medical Center is recognized by the PTEN Hamartoma Tumor Syndrome Foundation as a PTEN Clinical Center of Excellence. This means that our team has outstanding expertise in handling the health care needs of individuals with PHTS.
Cancer Risks Associated with a PTEN Mutation
Females with a PTEN P/LP variant may have more than a 60% lifetime risk for breast cancer and up to a 30% lifetime risk for uterine cancer. Males and females with the variant have up to a 35% lifetime risk for thyroid cancer, up to a 35% lifetime risk for kidney cancer, a 20% lifetime risk for colon cancer, and a 5-10% risk for melanoma (skin cancer).